Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
CDK4/6 inhibitors (CDK4/6i) have significantly impacted on the treatment of HR + HER2 negative (HER2-) metastatic breast cancer (BC) when combined with endocrine therapy. Nonetheless, despite significant research efforts, the mechanisms of de novo and acquired resistance to CDK4/6i have not yet been...
Saved in:
Main Authors: | L. Foffano, L. Cucciniello, E. Nicolò, I. Migliaccio, C. Noto, C. Reduzzi, L. Malorni, M. Cristofanilli, L. Gerratana, F. Puglisi |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | Breast |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977624001942 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01) -
Influence of ethnicity on cyclin-dependent kinase inhibitor efficacy and toxicity: A systematic review and meta-analysis
by: Roberto Buonaiuto, et al.
Published: (2025-02-01) -
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer
by: Brenno Pastò, et al.
Published: (2025-02-01) -
Analysis of Patristic Interpretation of the “Shema” in Deuteronomy 6:4-5
by: Isaac Boaheng
Published: (2024-09-01) -
Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)